1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

Summary

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck’s Gardasil, with GlaxoSmithKline’s (GSK’s) HPV vaccine Cervarix providing the only competition. The introduction of Merck’s nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

In 2006 Gardasil (marketed as Silgard in Germany) became the first vaccine approved for prophylactic protection against HPV infection. Gardasil was primarily developed and marketed by Merck, under license from Australian biotechnology company CSL, which markets the vaccine in Australia and New Zealand. Gardasil is a quadrivalent vaccine containing recombinant virus-like particles (VLPs) of the L1 capsid protein from the HPV strains 6, 11, 16 and 18, combined with an aluminum adjuvant (amorphous aluminum hydroxyphosphate sulfatez

Scope

- Overview of HPV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Gardasil including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Gardasil for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada and Australia

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HPV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Gardasil performance
- Obtain sales forecast for Gardasil from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Canada and Australia)

Table Of Contents

Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Related Reports 9
3 Disease Overview 10
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 11
3.2 Symptoms 13
4 Vaccination Recommendations and Coverage Rates 15
4.1 Vaccination Recommendations Overview 15
5 Competitive Assessment 17
5.1 Overview 17
5.2 Strategic Competitor Assessment 17
6 Gardasil 20
6.1 Overview 20
6.2 Efficacy 21
6.3 Safety 23
6.4 SWOT Analysis 24
6.5 Forecast 25
7 Appendix 26
7.1 Bibliography 26
7.2 Abbreviations 33
7.3 Methodology 35
7.4 Forecasting Methodology 35
7.4.1 Vaccine Coverage 36
7.4.2 Vaccine Approval versus Routine Schedule Inclusion 36
7.4.3 General Pricing Assumptions 37
7.4.4 Individual Drug Assumptions 38
7.5 Physicians and Specialists Included in this Study 39
7.6 About the Author(s) 42
7.6.1 Author(s) 42
7.6.2 Therapy Area Director 42
7.6.3 Global Head of Healthcare 43
7.7 About GlobalData 44
7.8 Disclaimer 44

1.1 List of Tables

Table 1: Histological Progression Towards Cervical Cancer 12
Table 2: Diseases Associated with HPV Infection and Their Associated Symptoms 14
Table 3: HPV Vaccine Recommendation Agencies by Country 16
Table 4: Targeted Group(s) for Recommended Immunization and Most-Administered HPV Vaccine by Country in the Global Markets, 2014 16
Table 5: Marketed Vaccines for HPV, 2014 19
Table 6: Product Profile - Gardasil 21
Table 7: Phase III Efficacy Trials - Gardasil 23
Table 8: Safety Profile - Gardasil 24
Table 9: Gardasil SWOT Analysis, 2014 24
Table 10: Global Sales Forecasts ($m) for Gardasil, 2012-2022 25
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 41

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

This cancer vaccines report by BCC Research explores present and future strategies within the market which includes prophylactic vaccines and therapeutic vaccines. Use this report to: - Analyze the global ...

Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Veterinary vaccines are extensively used in the prevention of life-threatening animal diseases. This report on the global veterinary vaccines market analyzes the current and future prospects of the market. ...

Vaccines Market by Technology, Disease Indication, End User & Type - Forecasts to 2021

Vaccines Market by Technology, Disease Indication, End User & Type - Forecasts to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The vaccines market is expected to reach USD 48.03 billion by 2021 from USD 32.24 billion in 2016 at a CAGR of 8.3%. The global vaccines market is segmented based on technology, type, disease indication, ...

Global Vaccine Adjuvants Market

August 2016 $ 4250

Global Veterinary Vaccines Market

October 2016 $ 4250

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.